Clinical Trial Update: Study of Anlotinib in Non-squamous NSCLC Patients Who Failed First-Line（ALTER-L020） [Phase 4]

View source ↗

Summary

Phase 4 study updates the use of anlotinib in patients with non-squamous non-small cell lung cancer after failure of first-line therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)

Snippet

Sponsor: First Affiliated Hospital Xi'an Jiaotong University | Conditions: Non-squamous NSCLC | Phase 4 | Status: UNKNOWN